Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.64 |
| ▸ | TK2 | O00142 | 3/20 | 0.64 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872494 | 0.83 | TK1 (0.60) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL5872491 | 0.83 | TK1 (0.60) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL28219421 | 0.83 | TK1 (0.62) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL12718344 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL12296879 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL14596596 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL767986 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL21078835 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL10382149 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 | |
| Doxribtimine SCHEMBL3437224 | 0.83 | TK1 (0.73) | TK1TK2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208190-A1 | LUMINESCENT METAL ION COMPLEXES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119781-B2 | Luminescent metal ion complexes | BIOSEARCH TECHNOLOGIES, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100130733-A1 | LUMINESCENT METAL ION COMPLEXES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7635762-B2 | Luminescent metal ion complexes | BIOSEARCH TECHNOLOGIES, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20040146895-A1 | Luminescent metal ion complexes | BIOSEARCH TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004037907-A2 | LUMINESCENT METAL ION COMPLEXES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146895-A1 | Luminescent metal ion complexes | SLC30A6, SLC39A14, SLC39A3 | TK1 2815/4885TK2 2067/4885RNASE1 2176/4885 |
| US-20100130733-A1 | LUMINESCENT METAL ION COMPLEXES | SLC30A6, SLC39A14, SLC39A3 | TK1 2815/4885TK2 2067/4885RNASE1 2176/4885 |
| US-20120208190-A1 | LUMINESCENT METAL ION COMPLEXES | SLC30A6, SLC39A14, SLC39A3 | TK1 2815/4885TK2 2067/4885RNASE1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.